Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Cevidoplenib in Healthy Men
NCT05042986Phase 1Completed
- Sponsor
- Oscotec Inc.
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cevidoplenib in rheumatoid arthritis (RA) and immune thrombocytopenia (ITP), sponsored by Oscotec Inc. Primary endpoints: Area under the concentration-time curve from time zero to infinity at Day 43, Area under the concentration-time curve from time zero to the last quantifiable concentration at Day 43 and 10 more. Started Aug 2021; status: completed.
02
Drugs
cevidoplenib
03
Conditions
rheumatoid arthritis (RA)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05042986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042986.